2.5 0.12 (5.04%) | 07-26 16:00 | |||||||||||||
|
|
Short term | ![]() ![]() ![]() |
|||
Mid term | ![]() |
|||
Targets | 6-month : | 3.34 | 1-year : | 3.84 |
Resists | First : | 2.86 | Second : | 3.28 |
Pivot price | 2.59 ![]() |
|||
Supports | First : | 2.18 | Second : | 1.81 |
MAs | MA(5) : | 2.43 | MA(20) : | 2.53 ![]() |
MA(100) : | 3.31 ![]() |
MA(250) : | 2.92 ![]() |
|
MACD | MACD : | -0.1 ![]() |
Signal : | -0.1 ![]() |
%K %D | K(14,3) : | 21.4 ![]() |
D(3) : | 21.5 ![]() |
RSI | RSI(14): 46.3 ![]() |
|||
52-week | High : | 5.51 | Low : | 1.27 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ IPSC ] has closed above bottom band by 41.2%. Bollinger Bands are 2.9% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
If tomorrow: | Open lower | Open higher |
High: | 2.52 - 2.53 | 2.53 - 2.54 |
Low: | 2.33 - 2.34 | 2.34 - 2.35 |
Close: | 2.48 - 2.5 | 2.5 - 2.52 |
Century Therapeutics, Inc., a biotechnology company, develops transformative allogeneic cell therapies for the treatment of solid tumor and hematological malignancies. The company's lead product candidate is CNTY-101, an allogeneic, induced pluripotent stem cells (iPSCs)-derived chimeric antigen receptors (CAR)-iNK cell therapy targeting CD19 for relapsed, refractory B-cell lymphoma. It is also developing CNTY-103, a CAR-iNK candidate targeting CD133 + EGFR for recurrent glioblastoma; CNTY-102, a CAR-iT targeting CD19 + CD79b for relapsed, refractory B-cell lymphoma and other B-cell malignancies; CNTY-104, a CAR-iT or CAR-iNK multi-specific candidate for acute myeloid leukemia; and CNTY-106, a CAR-iNK or CAR-iT multi-specific candidate for multiple myeloma. Century Therapeutics, Inc. was founded in 2018 and is headquartered in Philadelphia, Pennsylvania.
Mon, 22 Jul 2024
Mirae Asset Global Investments Co. Ltd. Invests $47,000 in Century Therapeutics, Inc. (NASDAQ:IPSC) - Defense World
Wed, 17 Jul 2024
Short Interest in Century Therapeutics, Inc. (NASDAQ:IPSC) Rises By 14.7% - MarketBeat
Tue, 16 Jul 2024
Great week for Century Therapeutics, Inc. (NASDAQ:IPSC) institutional investors after losing 7.4% over the previous year - Simply Wall St
Tue, 16 Jul 2024
Century Therapeutics (NASDAQ:IPSC) Trading Down 7.7% - Defense World
Tue, 09 Jul 2024
Century Therapeutics (IPSC) Moves to Buy: Rationale Behind the Upgrade - Yahoo Finance
Thu, 11 Apr 2024
Century Therapeutics Strengthens Position in Autoimmune - GlobeNewswire
Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
Exchange:
NASDAQ
|
|
Sector:
Healthcare
|
|
Industry:
Biotechnology
|
|
Shares Out | 0 (M) |
Shares Float | 85 (M) |
Held by Insiders | 3.778e+007 (%) |
Held by Institutions | 28.2 (%) |
Shares Short | 1,610 (K) |
Shares Short P.Month | 0 (K) |
EPS | -1.1105e+008 |
EPS Est Next Qtrly | 0 |
EPS Est This Year | 0 |
EPS Est Next Year | 0 |
Book Value (p.s.) | 0 |
Profit Margin | 0 % |
Operating Margin | -3 % |
Return on Assets (ttm) | 661.8 % |
Return on Equity (ttm) | -19.4 % |
Qtrly Rev. Growth | 1.37e+006 % |
Gross Profit (p.s.) | -35.93 |
Sales Per Share | -41.91 |
EBITDA (p.s.) | 0 |
Qtrly Earnings Growth | -2.3 % |
Operating Cash Flow | 0 (M) |
Levered Free Cash Flow | -89 (M) |
PE Ratio | -0.01 |
PEG Ratio | 0 |
Price to Book value | 0 |
Price to Sales | -0.06 |
Price to Cash Flow | 1.27 |
Dividend | 0 |
Forward Dividend | 1.79e+006 |
Dividend Yield | 0% |
Dividend Pay Date | Invalid DateTime. |
Ex-Dividend Date | Invalid DateTime. |